DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Aug 2019 |
  • Pages : 206 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

DNA Repair Drugs Market – Breakthrough for Cancer Patients

DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage results in genetic disorders, however the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs such as PARP inhibitors and other DNA repair drugs help to treat diseases with genetic aberrations.

The global DNA repair drugs market size was valued at US$ 461.3 Mn in 2017, and is expected to exhibit a CAGR of 32.4% over the forecast period (2018–2026).

Figure 1. Global DNA Repair Drugs Market Value (US$ Mn), by Region, 2018

DNA Repair Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies by manufacturers to increase and expand their product portfolio in the international markets are factors propelling growth of the global DNA repair drugs market

Increasing incidence of cancer is expected to drive the global DNA repair drugs market growth over the forecast period. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018.

Moreover, increasing drug approval by key players in order to address demand for efficient therapeutics, is expected to propel growth of the market over the forecast period. In October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).

However, Delays in regulatory approvals lead to delay in marketing of the product, which can adversely affect the revenue generation of the manufacturer. Similarly, delay in post approval of the drug product for other therapeutic indication results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products.

Figure 2. Global DNA Repair Drugs Market Share (%), by Drug Type, (2018-2026)

DNA Repair Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Rising prevalence of cancer, as well as increasing collaborations and acquisitions by key players is expected to boost the market growth

North America is expected to dominate the global DNA repair drugs market over the forecast period owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region.

Market players are engaged in research and development activities in order to meet the rising demand DNA repair drugs. In May 2019, Clovis Oncology, Inc., collaborated with Bristol-Myers Squibb Company and Foundation Medicine Inc. to initiate phase II study for evaluating rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometroid ovarian cancer.

Key Players

Major players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.

Market Dynamics

Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.

Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.

Key features of the study:

  • This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global DNA repair drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

 Detailed Segmentation:

  • Global DNA Repair Drugs Market, By Drug Type:
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • Global DNA Repair Drugs Market, By Application:
    • Ovarian Cancer
    • Breast Cancer
  • Global DNA Repair Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global DNA Repair Drugs Market, By Region:
    • North America
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
  • AstraZeneca Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Pfizer, Inc.
  • Clovis Oncology Inc.
  • AbbVie Inc.
  • Bristol Myers Squibb
  • Merck KGaA
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • Karyopharm Therapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Pricing Analysis
    • PEST Analysis
    • Epidemiology
  4. Global DNA Repair Drugs Market, By Drug Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Niraparib (Zejula)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Olaparib (Lynparza)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Rucaparib (Rubraca)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Talazoparib (Talzenna)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global DNA Repair Drugs Market, By Application, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Ovarian Cancer
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global DNA Repair Drugs Market , By Distribution Channel, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global DNA Repair Drugs Market , By Region, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • AstraZeneca Plc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Clovis Oncology Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol Myers Squibb
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Genentech, Inc.
        • Company Overview
        • Product Type Portfolio
        • Key Highlights
        • Market Strategies
      • Artios Pharma
        • Company Overview
        • Product Type Portfolio
        • Key Highlights
        • Market Strategies
      • Repare Therapeutics Inc.
        • Company Overview
        • Product Type Portfolio
        • Key Highlights
        • Market Strategies
      • Sierra Oncology, Inc.
        • Company Overview
        • Product Type Portfolio
        • Key Highlights
        • Market Strategies
      • Karyopharm Therapeutics Inc.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ono Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Jiangsu Hengrui Medicine Co., Ltd.
        • Company Overview
        • Product Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 31 market data tables and 24 figures on "DNA Repair Drugs Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.